Heron Therapeutics Target of Unusually High Options Trading (NASDAQ:HRTX)

Heron Therapeutics, Inc. (NASDAQ:HRTX) was the target of some unusual options trading activity on Tuesday. Traders bought 11,901 call options on the stock. This is an increase of 1,867% compared to the average volume of 605 call options.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the company. Needham & Company LLC reiterated a “buy” rating and set a $4.00 target price on shares of Heron Therapeutics in a report on Friday, April 11th. StockNews.com downgraded Heron Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, March 8th.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of HRTX. RFP Financial Group LLC acquired a new stake in Heron Therapeutics in the 1st quarter valued at about $26,000. Nicolet Advisory Services LLC acquired a new stake in shares of Heron Therapeutics in the fourth quarter valued at approximately $25,000. Valeo Financial Advisors LLC boosted its stake in shares of Heron Therapeutics by 34.1% during the 1st quarter. Valeo Financial Advisors LLC now owns 18,152 shares of the biotechnology company’s stock worth $40,000 after acquiring an additional 4,619 shares during the period. Argent Advisors Inc. acquired a new position in shares of Heron Therapeutics during the 4th quarter worth approximately $31,000. Finally, Focus Partners Wealth bought a new stake in Heron Therapeutics in the 4th quarter valued at $31,000. Institutional investors own 80.01% of the company’s stock.

Heron Therapeutics Stock Up 12.4 %

HRTX traded up $0.27 during trading hours on Tuesday, hitting $2.40. 4,972,983 shares of the company’s stock were exchanged, compared to its average volume of 2,340,819. The stock has a market cap of $365.31 million, a price-to-earnings ratio of -13.30 and a beta of 1.33. Heron Therapeutics has a 1-year low of $1.04 and a 1-year high of $3.93. The stock’s 50-day moving average is $2.19 and its two-hundred day moving average is $1.81.

Heron Therapeutics (NASDAQ:HRTX) last announced its quarterly earnings data on Tuesday, May 6th. The biotechnology company reported $0.01 earnings per share for the quarter, beating the consensus estimate of ($0.02) by $0.03. On average, equities research analysts anticipate that Heron Therapeutics will post -0.13 EPS for the current year.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.